About The Study: Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from 2022 to 2023. Although spending for certain GLP-1 ...

Study: Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review. Image Credit: Kmpzzz/Shutterstock.com In a recent study published ...

UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon. It has ...

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently licensed for the treatment of type 2 diabetes mellitus and obesity, offer a novel, multilayered mechanism for intervention in ...

pennmedicine.upenn.edu Background/aims Glucagon-like peptide-1 receptor (GLP-1R) agonists regulate blood glucose and are commonly used to treat type 2 diabetes mellitus. Recent work showed that ...

ABSTRACT: The increasing use of glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide, for weight management has sparked interest in understanding their broader physiological ...

A groundbreaking study published in the journal Current Neuropharmacology highlights a concerning potential link between Glucagon-like Peptide-1 (GLP1) receptor agonists-widely used in blockbuster ...

Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral ...

A new international study reveals a possible connection between GLP1 receptor agonists—used in drugs like Ozempic—and ...